Clinical Trial Update: Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of an mTOR inhibitor for vascular malformations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vascular Malformations

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Conditions: Cardiovascular Abnormalities | Phase 3 | Status: COMPLETED